Predictive Value of the CRP/Albumin Ratio in Mortality Prediction in Hip Fracture Surgery Patients Admitted to Intensive Care
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Patient Selection
2.3. Data Collection
2.4. Laboratory Parameters
2.5. Endpoints
2.6. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Taylor, N.F.; Rimayanti, M.U.; Peiris, C.L.; Snowdon, D.A.; Harding, K.E.; Semciw, A.I.; O’Halloran, P.D.; Wintle, E.; Williams, S.; Shields, N. Hip fracture has profound psychosocial impacts: A systematic review of qualitative studies. Age Ageing 2024, 53, afae194. [Google Scholar] [CrossRef] [PubMed]
- Ye, C.; Morin, S.N.; Lix, L.M.; McCloskey, E.V.; Johansson, H.; Harvey, N.C.; Kanis, J.A.; Leslie, W.D. Age at First Fracture and Later Fracture Risk in Older Adults Undergoing Osteoporosis Assessment. JAMA Netw. Open 2024, 7, e2448208. [Google Scholar] [CrossRef] [PubMed]
- Hamdan, M.; Haddad, B.I.; Almohtasib, J.; Eid, M.; Al-Din, T.J.; Rayyan, H.A.; Altantawi, A.M.; Akaheal, A.S.; Alshrouf, M.A. Postoperative pneumonia after femoral fracture surgery: An in-depth retrospective analysis. BMC Musculoskelet. Disord. 2024, 25, 413. [Google Scholar] [CrossRef] [PubMed]
- Ran, S.; Yu, Q.; Fu, M.; Hou, Z.; Wang, Z. Risk factors and prognosis of postoperative acute myocardial infarction in elderly hip fracture patients combined with coronary heart disease. J. Orthop. Surg. Res. 2024, 19, 306. [Google Scholar] [CrossRef] [PubMed]
- Tantigate, D.; Jansatjawan, N.; Adulkasem, N.; Ramart, P.; Riansuwan, K. Risk factors for postoperative urinary retention in fragility hip fracture patients: A prospective study. BMC Geriatr. 2024, 24, 483. [Google Scholar] [CrossRef] [PubMed]
- Li, L.; Zinger, J.; Sassen, S.D.; Juffermans, N.P.; Koch, B.C.; Endeman, H. The relation between inflammatory biomarkers and drug pharmacokinetics in critically ill patients. Crit. Care 2024, 28, 376. [Google Scholar] [CrossRef] [PubMed]
- Schnell, S.; Friedman, S.M.; Mendelson, D.A.; Bingham, K.W.; Kates, S.L. The 1-year mortality of patients treated in a hip fracture program for elders. Geriatr. Orthop. Surg. Rehabil. 2010, 1, 6–14. [Google Scholar] [CrossRef] [PubMed]
- Gibson, A.A.; Hay, A.W.; Ray, D.C. Patients with hip fracture admitted to critical care. Injury 2014, 45, 1066–1070. [Google Scholar] [CrossRef] [PubMed]
- Monserrat, J.; Asunsolo, A.; Gómez-Lahoz, A.; Ortega, M.A.; Gasalla, J.M.; Gasulla, Ó.; Fortuny-Profitós, J.; Mazaira-Font, F.A.; Román, M.T.; Arranz, A.; et al. Impact of the Innate Inflammatory Response on ICU Admission and Death in Hospitalized Patients with COVID-19. Biomedicines 2021, 9, 1675. [Google Scholar] [CrossRef] [PubMed]
- Capkin, S.; Guler, S.; Ozmanevra, R. C-Reactive Protein to Albumin Ratio May Predict Mortality for Elderly Population Who Undergo Hemiarthroplasty Due to Hip Fracture. J. Investig. Surg. 2021, 34, 1272–1277. [Google Scholar]
- Kim, B.G.; Lee, Y.-K.; Park, H.-P.; Sohn, H.-M.; Oh, A.-Y.; Jeon, Y.-T.; Koo, K.-H. C-reactive protein is an independent predictor for 1-year mortality in elderly patients undergoing hip fracture surgery. Medicine 2016, 95, e5152. [Google Scholar] [CrossRef] [PubMed]
- Borge, S.J.; Lauritzen, J.B.; Jørgensen, H.L. Hypoalbuminemia is associated with 30-day mortality in hip fracture patients independently of body mass index. Scand. J. Clin. Lab. Investig. 2022, 82, 571–575. [Google Scholar] [CrossRef]
- Gibbs, J.; Cull, W.; Henderson, W.; Daley, J.; Hur, K.; Khuri, S.F. Preoperative serum albumin level as a predictor of operative mortality and morbidity. Arch. Surg. 1999, 134, 36–42. [Google Scholar] [CrossRef]
- Ranzani, O.T.; Zampieri, F.G.; Forte, D.N.; Azevedo, L.C.P.; Park, M. C-reactive protein/albumin ratio predicts 90-day mortality of septic patients. PLoS ONE 2013, 8, e59321. [Google Scholar] [CrossRef] [PubMed]
- Oh, T.K.; Song, I.A.; Lee, J.H. Clinical usefulness of C-reactive protein to albumin ratio in predicting mortality in critically ill patients. Sci. Rep. 2018, 8, 16121. [Google Scholar] [CrossRef]
- Cacciola, G.; Mancino, F.; Holzer, L.A.; De Meo, F.; De Martino, I.; Bruschetta, A.; Risitano, S.; Sabatini, L.; Cavaliere, P. Predictive value of the C-reactive protein to albumin ratio in 30-day mortality after hip fracture in elderly population. J. Clin. Med. 2023, 12, 4544. [Google Scholar] [CrossRef] [PubMed]
- Long, A.; Yang, D.; Jin, L.; Zhao, F.; Wang, X.; Zhang, Y.; Liu, L. Admission inflammation markers influence long-term mortality in elderly patients undergoing hip fracture surgery. Orthop. Surg. 2024, 16, 38–46. [Google Scholar] [CrossRef] [PubMed]
- Aydın, A.; Kaçmaz, O. CRP/albumin ratio in predicting 1-year mortality in elderly patients undergoing hip fracture surgery. Eur. Rev. Med. Pharmacol. Sci. 2023, 27, 8438–8446. [Google Scholar] [CrossRef] [PubMed]
- Soysal, P.; Stubbs, B.; Lucato, P.; Luchini, C.; Solmi, M.; Peluso, R.; Sergi, G.; Isik, A.T.; Manzato, E.; Maggi, S.; et al. Inflammation and frailty in the elderly: A systematic review and meta-analysis. Ageing Res. Rev. 2016, 31, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Yoon, J.H.; Pinsky, M.R. Predicting adverse hemodynamic events in critically ill patients. Curr. Opin. Crit. Care 2018, 24, 196–203. [Google Scholar] [CrossRef] [PubMed]
- Oh, A.R.; Ryu, J.-A.; Lee, S.J.; Kim, C.S.; Lee, S.M. Association between Inflammation-Based Prognostic Markers and Mortality in Patients Admitted to Intensive Care Units. Diagnostics 2024, 14, 1709. [Google Scholar] [CrossRef] [PubMed]

| Variable | Total (N = 134) | 30-Day Mortality (n = 14) | p | 31–90-Day Mortality (n = 16) | p |
|---|---|---|---|---|---|
| Age (years) | 75.4 ±16.9 | 84.3 ±9.9 | 0.225 | 69.2 ±14.8 | 0.073 |
| Gender, Female/Male | 68 (50.7%)/66 (49.3%) | 6 (42.9%)/8 (57.1%) | – | 12 (75%)/4 (25%) | – |
| Comorbidities, Yes/No | 104 (77.6%)/30 (22.4%) | 9 (64.3%)/5 (35.7%) | 0.206 | 16 (100%)/0 (0%) | 0.393 |
| Diabetes Mellitus, Yes/No | 27 (20.1%)/107 (79.9%) | 2 (14.3%)/12 (85.7%) | 0.563 | 5 (31.3%)/11 (68.7%) | 0.622 |
| Hypertension, Yes/No | 53 (39.6%)/81 (60.4%) | 4 (28.6%)/10 (71.4%) | 0.375 | 10 (62.5%)/6 (37.5%) | 0.366 |
| Malignancy, Yes/No | 7 (5.2%)/127 (94.8%) | 1 (7.1%)/13 (92.9%) | 0.733 | 2 (12.5%)/14 (87.5%) | 0.182 |
| Cerebrovascular Disease, Yes/No | 8 (6%)/126 (94%) | 0 (0%)/14 (100%) | 0.319 | 4 (25%)/12 (75%) | 0.053 |
| Chronic Kidney Disease, Yes/No | 5 (3.7%)/129 (96.3%) | 0 (0%)/14 (100%) | 0.436 | 1 (6.3%)/15 (93.7%) | 0.896 |
| Cardiac Problem, Yes/No | 42 (31.3%)/92 (68.7%) | 6 (42.8%)/8 (57.2%) | 0.326 | 6 (37.5%)/10 (62.5%) | 0.246 |
| Respiratory Disease, Yes/No | 20 (14.9%)/114 (85.1%) | 0 (0%)/14 (100%) | 0.319 | 3 (18.7%)/13 (81.3%) | 0.390 |
| Parameter | 30-Day Survivors | 30-Day Non-Survivors | p | 90-Day Survivors | 90-Day Non-Survivors | p |
|---|---|---|---|---|---|---|
| APACHE II | 17 (15–20) | 21 (19.75–28) | <0.001 | 17 (15–20) | 20 (18.25–25.25) | 0.002 |
| SAPS II | 35 (28–45) | 42 (26–56) | 0.008 | 34 (28–41.75) | 43 (29.5–52.5) | 0.018 |
| CRP/Albumin | 12.54 (4.4–27.32) | 98.47 (67.1–107.46) | 0.003 | 14.22 (11.45–22.46) | 37.07 (26.16–97.19) | <0.01 |
| CRP (mg/L) | 44 (16.37–87.57) | 107 (71.25–263.75) | 0.087 | 39.5 (13.95–77.37) | 113.5 (79.6–205) | 0.255 |
| Albumin (g/dL) | 3.3 (3.05–3.7) | 2.4 (2.12–3.02) | <0.001 | 3.3 (3.01–3.8) | 3.1 (2.4–3.3) | 0.004 |
| BUN (mg/dL) | 44 (33–61.75) | 61 (30–121) | 0.022 | 41 (32–58.75) | 64 (38–104.5) | 0.257 |
| Creatinine (mg/dL) | 0.91 (0.65–1.24) | 0.87 (0.68–1.31) | 0.025 | 0.9 (0.61–1.21) | 1.02 (0.74–1.42) | 0.099 |
| pH | 7.36 (7.32–7.40) | 7.35 (7.21–7.43) | <0.001 | 7.36 (7.32–7.39) | 7.37 (7.29–7.42) | 0.029 |
| Lactate (mmol/L) | 1.6 (1.1–2.4) | 2.8 (1.77–4.12) | 0.013 | 1.6 (1.12–2.67) | 1.8 (1.25–2.8) | 0.056 |
| Neutrophil (/mm3) | 7995 (5450–9940) | 21,850 (17,400–27,770) | 0.024 | 7795 (5300–9800) | 14,450 (8180–22,480) | 0.181 |
| Lymphocyte (/mm3) | 930 (690–1390) | 410 (360–612) | 0.021 | 915 (630–1390) | 755 (410–1040) | 0.194 |
| Neutrophil/Lymphocyte Ratio | 8.23 (5.27–12.26) | 52.99 (38.53–94.46) | 0.275 | 7.68 (5–12.42) | 16.75 (8.37–52.47) | 0.336 |
| Hospital Stay (days) | 6.5 (5–10) | 10.5 (4–19.75) | 0.020 | 6 (1–9) | 11 (5–22) | 0.015 |
| ICU Stay (days) | 2 (1–3) | 3.5 (2–13) | 0.003 | 4 (2–10) | 6 (4–10) | 0.001 |
| Inflammatory Burden Index | 291.15 (90.09–774.78) | 12,083.63 (6236.27–21,684.59) | 0.318 | 261.07 (87.06–708.73) | 1541.50 (712.96–11,527.65) | 0.318 |
| Variable | B | SE | Wald | df | p | Exp(B) | 95% CI for Exp(B) |
|---|---|---|---|---|---|---|---|
| CRP/Albumin | 0.047 | 0.011 | 18.331 | 1 | <0.001 | 1.048 | 1.026–1.071 |
| Urea | −0.008 | 0.005 | 2.826 | 1 | 0.093 | 0.992 | 0.982–1.001 |
| Neutrophil/Lymphocyte Ratio | −0.499 | 0.772 | 0.418 | 1 | 0.518 | 0.607 | 0.134–2.757 |
| Leukocyte | 0.086 | 0.039 | 4.891 | 1 | 0.027 | 1.089 | 1.010–1.175 |
| Hematocrit | −0.095 | 0.059 | 2.610 | 1 | 0.106 | 0.909 | 0.810–1.021 |
| Variable | B | SE | Wald | df | p | Exp(B) | 95% CI for Exp(B) |
|---|---|---|---|---|---|---|---|
| CRP/Albumin | 0.025 | 0.008 | 9.561 | 1 | 0.002 | 1.025 | 1.009–1.042 |
| Urea | 0.002 | 0.004 | 0.386 | 1 | 0.535 | 1.002 | 0.995–1.009 |
| Neutrophil/Lymphocyte Ratio | 0.005 | 0.015 | 0.098 | 1 | 0.755 | 1.005 | 0.975–1.036 |
| Leukocyte | 0.015 | 0.027 | 0.326 | 1 | 0.568 | 1.015 | 0.964–1.070 |
| Hematocrit | −0.034 | 0.034 | 1.045 | 1 | 0.307 | 0.966 | 0.905–1.032 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Yılmaz, A.; Soylu, V.G.; Taşkın, Ö.; Demir, U.; Küçük, B.T.; Yılmaz, Ö.; Aytaç, A.; Doğanay, Z. Predictive Value of the CRP/Albumin Ratio in Mortality Prediction in Hip Fracture Surgery Patients Admitted to Intensive Care. Life 2026, 16, 1215. https://doi.org/10.3390/life16081215
Yılmaz A, Soylu VG, Taşkın Ö, Demir U, Küçük BT, Yılmaz Ö, Aytaç A, Doğanay Z. Predictive Value of the CRP/Albumin Ratio in Mortality Prediction in Hip Fracture Surgery Patients Admitted to Intensive Care. Life. 2026; 16(8):1215. https://doi.org/10.3390/life16081215
Chicago/Turabian StyleYılmaz, Ayşe, Veysel Garani Soylu, Öztürk Taşkın, Ufuk Demir, Büşra Tanyıldızı Küçük, Özgür Yılmaz, Azra Aytaç, and Zahide Doğanay. 2026. "Predictive Value of the CRP/Albumin Ratio in Mortality Prediction in Hip Fracture Surgery Patients Admitted to Intensive Care" Life 16, no. 8: 1215. https://doi.org/10.3390/life16081215
APA StyleYılmaz, A., Soylu, V. G., Taşkın, Ö., Demir, U., Küçük, B. T., Yılmaz, Ö., Aytaç, A., & Doğanay, Z. (2026). Predictive Value of the CRP/Albumin Ratio in Mortality Prediction in Hip Fracture Surgery Patients Admitted to Intensive Care. Life, 16(8), 1215. https://doi.org/10.3390/life16081215

